BioLineRx Ltd.

Regulatory Filings • Jun 1, 2015

_________ false

C003������� �� ��� ��"�2PublicBIOLINE RX LTD9253Corporation no: 513398750Stock Exchange/Market: NASDAQ-SC2271381����� 19 , ������� 91450 , ,Tel: 02-5489100 , 02-5489116 Fax: 02-5489101E.mail address: info@BioLineRx.comReported via MAGNA: 01/06/2015              Time of broadcast: 13:50 13:42:48

Reference: 2015-02-036909

Israel Securities Authority		Tel Aviv Stock Exchange
www.isa.gov.il		www.tase.co.il

Other Report or AnnouncementRegulation 5 of the Securities Regulations, (Periodic and Immediate Reports of Foreign Corporation) 5761-2000 The corporation is a foreign private issuer as defined by U.S. Securities Laws.

Attached hereto is a report on	BioLineRx Announces Peer-Reviewed Publication of Phase 1/2 Trial Results for Novel Treatment for Non-Surgical Removal of Skin Lesions

6-K_BL5010_010615_isa.pdf

References of previous documents relating to this matter(the reference does not constitute incorporation by reference):
Previous names of reporting entity:
Date of revision of form structure: 15/04/2015
- - -
Name of the Signatory: : Kotler Norman Harold , Position of Signatory in the reporting corporation: General Counsel & Company Secretary , Name of Employer Company: .
Hartum Telephone: 02-5489100 , Facsimile: 02-5489101 , E-mail: normank@biolinerx.com 1